The National Institutes of Health (NIH), as well as the US Food and Drug Administration (FDA) and several medical bioresearchers, are developing standardised Covid-19 severity terminology and clinical trial templates to address biomarkers used in present clinical trials.

The workforce, ACTIV, is attempting to reach an agreement and issue recommendations as quickly as possible. Read more here.